Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets (Q36889961)

16 August 2017

1 reference

title

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets (English)

1 reference

16 August 2017

0 references

1 reference

1 reference

5

Kenneth C Anderson

1 reference

16 August 2017

4

Paul G Richardson

1 reference

16 August 2017

1

Teru Hideshima

1 reference

16 August 2017

Constantine S Mitsiades

series ordinal

2

object named as

Constantine Mitsiades

1 reference

16 August 2017

3

Giovanni Tonon

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

16 August 2017

Nature Reviews Cancer

1 reference

16 August 2017

7

1 reference

16 August 2017

8

1 reference

16 August 2017

585-598

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc2189

16 August 2017

0 references

cites work

Monoclonal gammopathy of undetermined significance

1 reference

31 March 2020

1 reference

Antitumor activity of thalidomide in refractory multiple myeloma

31 March 2020

1 reference

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

31 March 2020

1 reference

A phase 2 study of bortezomib in relapsed, refractory myeloma

31 March 2020

1 reference

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

31 March 2020

1 reference

Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications

31 March 2020

1 reference

Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line

31 March 2020

1 reference

DNA methylation profiles of lymphoid and hematopoietic malignancies

31 March 2020

1 reference

High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients

31 March 2020

1 reference

Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases

31 March 2020

1 reference

Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma

31 March 2020

1 reference

Ploidy status rarely changes in myeloma patients at disease progression.

31 March 2020

1 reference

Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma

31 March 2020

1 reference

Hypodiploidy is a major prognostic factor in multiple myeloma

31 March 2020

1 reference

The molecular classification of multiple myeloma

31 March 2020

1 reference

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

31 March 2020

1 reference

Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma

31 March 2020

1 reference

The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma

31 March 2020

1 reference

Chromosome translocations in multiple myeloma

31 March 2020

1 reference

Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell.

31 March 2020

1 reference

Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.

31 March 2020

1 reference

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

31 March 2020

1 reference

Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma

31 March 2020

1 reference

Molecular pathogenesis and a consequent classification of multiple myeloma

31 March 2020

1 reference

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.

31 March 2020

1 reference

The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells

31 March 2020

1 reference

In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression

31 March 2020

1 reference

A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript

31 March 2020

1 reference

Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases

31 March 2020

1 reference

Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy

31 March 2020

1 reference

Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.

31 March 2020

1 reference

Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hé

31 March 2020

1 reference

Clinical and biologic implications of recurrent genomic aberrations in myeloma

31 March 2020

1 reference

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma

31 March 2020

1 reference

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transpla

31 March 2020

1 reference

Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma

31 March 2020

1 reference

Multiple myeloma: evolving genetic events and host interactions

31 March 2020

1 reference

Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.

31 March 2020

1 reference

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

31 March 2020

1 reference

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials

31 March 2020

1 reference

Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14)

31 March 2020

1 reference

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma

31 March 2020

1 reference

High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis

31 March 2020

1 reference

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis

31 March 2020

1 reference

Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma.

31 March 2020

1 reference

Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341.

31 March 2020

1 reference

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

31 March 2020

1 reference

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions

31 March 2020

1 reference

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

31 March 2020

1 reference

Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation

31 March 2020

1 reference

Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3.

31 March 2020

1 reference

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

31 March 2020

1 reference

Cell responses to FGFR3 signalling: growth, differentiation and apoptosis

31 March 2020

1 reference

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

31 March 2020

1 reference

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

31 March 2020

1 reference

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

31 March 2020

1 reference

Advances in biology of multiple myeloma: clinical applications

31 March 2020

1 reference

Pathogenesis of myeloma bone disease

31 March 2020

1 reference

New potential targets for treating myeloma bone disease

31 March 2020

1 reference

Angiogenesis in multiple myeloma

31 March 2020

1 reference

Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma

31 March 2020

1 reference

Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100.

31 March 2020

1 reference

Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells

31 March 2020

1 reference

Integrin-mediated drug resistance in multiple myeloma

31 March 2020

1 reference

Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).

31 March 2020

1 reference

Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas

31 March 2020

1 reference

Soluble syndecan-1 promotes growth of myeloma tumors in vivo

31 March 2020

1 reference

Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis

31 March 2020

1 reference

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications

31 March 2020

1 reference

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

31 March 2020

1 reference

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

31 March 2020

1 reference

Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma

31 March 2020

1 reference

Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells

31 March 2020

1 reference

Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression

31 March 2020

1 reference

Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival

31 March 2020

1 reference

Endothelial cells in the bone marrow of patients with multiple myeloma

31 March 2020

1 reference

Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.

31 March 2020

1 reference

Novel therapeutic approaches targeting vascular endothelial growth factor and its receptors in haematological malignancies

31 March 2020

1 reference

Evidence for the secretion of an osteoclast stimulating factor in myeloma.

31 March 2020

1 reference

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

31 March 2020

1 reference

New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).

31 March 2020

1 reference

RANKL expression is related to the differentiation state of human osteoblasts.

31 March 2020

1 reference

RANK ligand and osteoprotegerin in myeloma bone disease.

31 March 2020

1 reference

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.

31 March 2020

1 reference

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

31 March 2020

1 reference

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

31 March 2020

1 reference

Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment

31 March 2020

1 reference

Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease

31 March 2020

1 reference

MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.

31 March 2020

1 reference

Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone

31 March 2020

1 reference

Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.

31 March 2020

1 reference

Chondroitin synthase 1 is a key molecule in myeloma cell-osteoclast interactions.

31 March 2020

1 reference

Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation

31 March 2020

1 reference

Cbfa1 as a regulator of osteoblast differentiation and function

31 March 2020

1 reference

Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.

31 March 2020

1 reference

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

31 March 2020

1 reference

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

31 March 2020

1 reference

Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo

31 March 2020

1 reference

Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation

31 March 2020

1 reference

Essential role of beta-catenin in postnatal bone acquisition

31 March 2020

1 reference

Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro

31 March 2020

1 reference

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

31 March 2020

1 reference

IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma

31 March 2020

1 reference

Transforming growth factor-beta increases interleukin-6 transcripts in osteoblasts

31 March 2020

1 reference

The ubiquitin-proteasome system and cellular proliferation and regulation in osteoblastic cells

31 March 2020

1 reference

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

31 March 2020

1 reference

Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment

31 March 2020

1 reference

Focus on multiple myeloma

31 March 2020

1 reference

A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.

31 March 2020

1 reference

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

31 March 2020

1 reference

Antimyeloma activity of heat shock protein-90 inhibition.

31 March 2020

1 reference

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

31 March 2020

1 reference

Using genomics to identify high-risk myeloma after autologous stem cell transplantation

31 March 2020

1 reference

Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma

31 March 2020

1 reference

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

31 March 2020

1 reference

Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling

31 March 2020

1 reference

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

31 March 2020

1 reference

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

31 March 2020

1 reference

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

31 March 2020

1 reference

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

31 March 2020

1 reference

The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.

31 March 2020

1 reference

Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding

31 March 2020

1 reference

Post-translational modifications of eukaryotic initiation factor-5A (eIF-5A) as a new target for anti-cancer therapy

31 March 2020

1 reference

Cyclin proteolysis as a retinoid cancer prevention mechanism

31 March 2020

1 reference

Regulation of cell proliferation by autocrine motility factor/phosphoglucose isomerase signaling

31 March 2020

1 reference

To cycle or not to cycle: a critical decision in cancer.

31 March 2020

1 reference

The RB and p53 pathways in cancer

31 March 2020

1 reference

FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies

31 March 2020

1 reference

Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma

31 March 2020

1 reference

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

31 March 2020

1 reference

Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells

31 March 2020

1 reference

A clinically relevant SCID-hu in vivo model of human multiple myeloma

31 March 2020

1 reference

The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis

31 March 2020

1 reference

Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1

31 March 2020

1 reference

Survival and proliferation factors of normal and malignant plasma cells

31 March 2020

1 reference

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

31 March 2020

1 reference

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

31 March 2020

1 reference

A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.

31 March 2020

1 reference

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)

31 March 2020

1 reference

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

31 March 2020

1 reference

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

31 March 2020

1 reference

Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

31 March 2020

1 reference

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

31 March 2020

1 reference

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

31 March 2020

1 reference

Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib

31 March 2020

1 reference

Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).

31 March 2020

1 reference

Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer

31 March 2020

1 reference

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

31 March 2020

1 reference

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

31 March 2020

1 reference

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

31 March 2020

1 reference

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

31 March 2020

1 reference

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

31 March 2020

1 reference

Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells

31 March 2020

1 reference

Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib

31 March 2020

1 reference

Identification of genes modulated in multiple myeloma using genetically identical twin samples

31 March 2020

1 reference

Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma.

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRC2189

1 reference

Dimensions Publication ID

16 August 2017

0 references

1 reference